Teva and fosun pharma enter into a strategic partnership to develop novel anti-pd1-il2 therapy (tev-56278) in immuno-oncology

Teva-engineered tev-56278 is an anti-pd1-il2 attenukine™ therapy in phase 1 for the treatment of various forms of cancer, including melanoma fosun pharma-teva collaboration agreement established with goal of accelerating clinical data generation for tev-56278 partnership leverages strategic relationships to enable research and development of innovative treatments to advance teva's pivot to growth strategy tel aviv, israel and shanghai , june 16, 2025 /prnewswire/ -- teva pharmaceutical industries ltd. (nyse and tase: teva) and shanghai fosun pharmaceutical (group) co., ltd.
TEVA Ratings Summary
TEVA Quant Ranking